U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Pharmacy Direct, PDU - 548625 - 05/18/2018
  1. Warning Letters


Pharmacy Direct, PDU MARCS-CMS 548625 —

Delivery Method:
Express Delivery

Recipient Name
Michael Rowen
Pharmacy Direct, PDU

8 The Green
Suite 5871
Dover, DE 19901
United States

Issuing Office:
Center for Food Safety and Applied Nutrition

United States



Black HHS-Blue FDA Logo





MAY 18 2018


Michael Rowen, President
Pharmacy Direct, Inc.
8 The Green
Suite 5871
Dover, DE 19901

Re: 548625

This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address www.solaricare.com in March 2018 and has determined that you market and take orders for the product Solaricare from the two web links on your website that direct your customers to your Pharmacy Direct website at http://www.pharmacydirect.com and your Amazon storefront page at https://www.amazon.com/dp/B00WING7PE?th=1. The claims on these websites establish that the product is a drug under section 201(g)(1)(B)  of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act.  You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov

An example of one of the website claims that provides evidence that your Solaricare product is intended for use as a drug includes:

• “SOLARICARE only contains one intredient [sic] Polypodium Leucotomos …. Used … for treating skin disorders such as psoriasis, eczema, polymorphic light eruption and sunburn."

Your Solaricare product is not generally recognized as safe and effective for the above referenced use and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. § 321(p)].  New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d),355(a)].  FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective. 

This letter is not an all-inclusive statement of violations associated with your product or its labeling, and we have not attempted to list here all of the products that are promoted on your website for intended uses that cause them to be drugs.  It is your responsibility to ensure that all products marketed by your firm comply with the Act and its implementing regulations.  We advise you to review your website, product labels, and other labeling for your products to ensure that the claims you make for your products do not reflect intended uses that cause the distribution of the products to violate the Act.

We request that you take prompt action to correct all violations associated with your products, including the violations identified in this letter. Failure to do so may result in enforcement action without further notice. The Act authorizes injunctions against manufacturers and distributors of illegal products and seizure of such products.

If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. Please notify this office in writing within fifteen (15) working days of the receipt of this letter as to the specific steps you have taken to correct the stated violations, including an explanation of each step being taken to identify violations and make corrections to ensure that similar violations will not recur. If the corrective action cannot be completed within fifteen working days, state the reason for the delay and the time frame within which the corrections will be implemented.

You should direct your written reply to Beth Tirio, Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835. If you have any questions regarding this letter, you may contact Ms. Tirio via email at beth.tirio@fda.hhs.gov.


William Correll
Office of Compliance
Center for Food Safety and Applied Nutrition
US Food and Drug Administration


Close Out Letter

Back to Top